In mucocutaneous pemphigus vulgaris, antibodies against both Dsg1 and Dsg3 are produced, resulting in involvement of both the skin and the mucous membranes. The mechanism of autoantibody ...

Tailoring rituximab treatment among patients with pemphigus based on the presence of predictors of early relapse reduced relapse rates at 12 months.

Pemphigus is a rare autoimmune blistering disease involving the skin and mucous epithelia ... the most frequent being pemphigus vulgaris (PV) and pemphigus foliaceous (PF). Histologically ...

The FDA has approved Genentech’s Rituxan (rituximab) for use in adults with moderate-to-severe pemphigus vulgaris (PV), making ... painful blistering of the skin and mucous membranes.

This is a schematic of how a "chimeric autoantibody receptor," or CAAR, that displays fragments of the autoantigen Dsg3 helps fight an autoimmune disease called pemphigus vulgaris, a condition in ...